Darwin Wealth Management LLC Sells 58,250 Shares of Dyne Therapeutics, Inc. $DYN

Darwin Wealth Management LLC decreased its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 33.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 115,267 shares of the company’s stock after selling 58,250 shares during the period. Darwin Wealth Management LLC owned 0.08% of Dyne Therapeutics worth $2,255,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in shares of Dyne Therapeutics by 27.6% during the 3rd quarter. Vanguard Group Inc. now owns 9,760,414 shares of the company’s stock worth $123,469,000 after buying an additional 2,109,257 shares during the period. TCG Crossover Management LLC boosted its holdings in shares of Dyne Therapeutics by 22.5% during the 3rd quarter. TCG Crossover Management LLC now owns 4,615,144 shares of the company’s stock worth $58,382,000 after buying an additional 848,484 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Dyne Therapeutics by 9.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,365,245 shares of the company’s stock worth $42,570,000 after buying an additional 278,466 shares during the period. Adage Capital Partners GP L.L.C. bought a new stake in shares of Dyne Therapeutics during the 2nd quarter worth about $30,378,000. Finally, Armistice Capital LLC boosted its holdings in shares of Dyne Therapeutics by 19.7% during the 3rd quarter. Armistice Capital LLC now owns 3,064,000 shares of the company’s stock worth $38,760,000 after buying an additional 504,000 shares during the period. Institutional investors own 96.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on DYN shares. Chardan Capital reaffirmed a “buy” rating and set a $38.00 target price on shares of Dyne Therapeutics in a report on Monday, March 9th. HC Wainwright reduced their target price on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, March 3rd. Oppenheimer raised shares of Dyne Therapeutics from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $11.00 to $40.00 in a report on Wednesday, December 10th. Morgan Stanley reduced their target price on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a report on Monday, March 2nd. Finally, Evercore cut their price objective on shares of Dyne Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Monday, December 15th. Three research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $35.14.

Dyne Therapeutics Stock Performance

NASDAQ DYN opened at $18.38 on Thursday. The company has a quick ratio of 22.25, a current ratio of 22.25 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $3.03 billion, a P/E ratio of -5.19 and a beta of 1.29. Dyne Therapeutics, Inc. has a 12-month low of $6.36 and a 12-month high of $25.00. The firm has a 50-day moving average price of $17.18 and a two-hundred day moving average price of $17.89.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02). Analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, Director Brian S. Posner acquired 3,000 shares of the business’s stock in a transaction on Friday, March 6th. The stock was purchased at an average price of $15.06 per share, with a total value of $45,180.00. Following the acquisition, the director directly owned 11,500 shares of the company’s stock, valued at approximately $173,190. This trade represents a 35.29% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 14.14% of the stock is owned by corporate insiders.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.